Clinical trial
Omr-IgG-am(Trademark) for Treating Patients With or at High Risk for West Nile…
NCT00069316 · National Institutes of Health Clinical Center (CC), NIH · Completed
Key facts
| NCT number | NCT00069316 |
|---|---|
| Title | Omr-IgG-am(Trademark) for Treating Patients With or at High Risk for West Nile Virus Disease |
| Official title | A Phase I/II Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin G (Omr-IgG-am) Containing High Anti-West Nile Virus Antibody Titers in Patients With, or at High Risk for Progression to West Nile Virus(WNV) |
| Lead sponsor | National Institutes of Health Clinical Center (CC), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | West Nile Virus |
| Intervention type | Drug |
| Interventions | Omr-IgG-am |
| Enrollment | 2 |
| Start date | Sep 22, 2003 |
| Primary completion | Jun 27, 2007 |
| Completion | Jun 27, 2007 |
| First posted | Sep 23, 2003 |
| Last update posted | Jul 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: